 EMERYVILLE, Calif., Nov. 05, 2020 GLOBE NEWSWIRE -- Gritstone Oncology, Inc. Nasdaq: GRTS, a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today reported financial results for the third quarter ended September 30, 2020 and reviewed business highlights. 